Renal Denervation Market Size, Share & Trends Analysis Report By Technology (Micro-Infusion, Ultrasound, Radiofrequency Based), By Region (Europe, APAC, MEA, North America), And Segment Forecasts, 2018 - 2026

Report Overview

The global renal denervation market size was estimated at USD 41.7 million in 2017 and is anticipated to expand at a CAGR of 43.2% over the forecast period. Factors, such as growing cases of therapy-resistant hypertension is one of the key growth-driving factors for the market. Hypertension is one of the most common diseases in the world.

As per the Centers for Disease Control and Prevention (CDC), in 2013, more than 360,000 people in America died due to high blood pressure. The occurrence of hypertension has increased from 17,307 per 100,000 in 1990 to 20,525 per 100,000 in 2015. However, renal denervation therapy has shown a positive result in reducing hypertension. Thus, the advantages offered by these therapies, such as permanent effect, reduced treatment time, and higher safety, are boosting the market growth. Furthermore, the advancement of renal denervation devices is likely to drive the market.

For example, the development of catheter-based interventional therapies to ablate renal nerve has shown impressive results in treating blood pressure in patients having complaints of resistant hypertension. Also, the catheter-based procedure appears to be safer for patients and facilitates the denervation of selected nerves.

Availability of alternative and improved technology, such as micro-infusion, for renal denervation systems and improving healthcare infrastructure in emerging economies, are also anticipated to boost the market growth. For instance, Mercator MedSystem’s micro-infusion based renal denervation system. It delivers agents at a specific site to denervate the renal artery, thus reducing the blood pressure in patients.

Technology Insights

On the basis of technology, the market is segmented into radiofrequency, ultrasound, and micro-infusion based renal denervation. The radiofrequency segment held 75.15% of the total market share in 2017, owing to its advantages, such as safety and time efficiency. Ultrasound segment is anticipated to expand at the highest CAGR as it overcomes the limitations of radiofrequency based systems. Ultrasound energy with high-frequency sound waves ablates the nerves without getting in direct contact with the tissues, thus reducing injuries to the renal arteries.

Regional Insights

In terms of region, Europe led the renal denervation market in 2017 and is anticipated to maintain dominance even during the forecast period. This is attributed to increasing R&D activities for the development of efficient devices. Increasing cases of drug-resistant hypertension will also contribute to the region’s growth. As reported by the National Center for Biotechnology Information (NCBI), in the U.K., the cases of hypertension have increased from 3.79 cases per 100 people in 2000 to 6.46 cases per 100 people in 2015. Furthermore, device approval in the European region is also anticipated to favor market growth.

North America is projected to follow Europe, in terms of revenue generation, during the forecast period due to the rising number of filings for FDA approvals in the U.S. For instance, Medtronic has received FDA approval to start an Investigational Device Exemption (IDE) pivotal trial for evaluating the Symplicity Spyral renal denervation system in the patients with hypertension. Increasing the incidence of uncontrolled hypertension is also one of the key factors responsible for the region’s growth.

Asia Pacific (APAC) region is anticipated to witness the fastest growth over the forecast period due to rising cases of diabetes, obesity, and other lifestyle diseases. Moreover, the presence of a large target population base in developing economies like Japan and China are the main drivers for the market growth in APAC.

Renal Denervation Market Share Insights

Some of the companies in this market are Medtronic PLC; Cardiosonic, Inc.; Kona Medical, Inc.; Abbott Laboratories; Ablative Solutions, Inc.; Renal Dynamics; Mercator MedSystems, Inc.; ReCor Medical, Inc.; Boston Scientific Corp.; and Symple Surgical, Inc. Various strategies, such as R&D, M&A, and product launch, are being adopted by these companies to strengthen their market position. For instance, in August 2014, Kona Medical initiated the WAVE IV clinical trial of its non-invasive Surround Sound Hypertension Therapy System. The company announced that the trail will treat 132 subjects at sites in Australia, New Zealand, South America and, Europe.

Renal Denervation Market Report Scope

Segments Covered in the Report

This report forecasts revenue and volume growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2026. For the purpose of this study, Grand View Research has segmented the global renal denervation market report on the basis of technology and region:

• Technology Outlook (Revenue, USD Million, 2014 - 2026)

  • Radiofrequency-based

  • Ultrasound-based

  • Micro-Infusion-based

• Regional Outlook (Revenue, USD Million, 2014 - 2026)

  • North America

    • The U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

  • Asia Pacific

    • Japan

    • China

  • Latin America

    • Brazil

    • Mexico

  • Middle East & Africa

    • South Africa

    • Saudi Arabia